Designed for ease of use and minimal investment, the Olink Signature Q100 broadens the reach of advanced multiplexing to more researchers, facilitating impactful discoveries

Products:

Olink Explore HT

Developed for specificity, validated for quality

Our dual-recognition, DNA-coupled technology delivers industry-leading specificity, eliminating wrong targets, misinterpretation and wasted resources. Every assay undergoes a rigorous validation process, ensuring quality data you can trust.

Olink Flex

Olink Flex enables targeted research studies by combining up to 21 biomarkers from our extensive library with minimal sample consumption.

Olink Target 48

Olink Target 48 Cytokine and the new Olink Target 48 Immune Surveillance are two carefully designed panels. Each contains up to 45 immune-related proteins and requires just 1 μL of sample. These two panels can be combined and processed simultaneously, enabling a comprehensive analysis of immune mediators.

Aging

Aging is a fundamental biological process with an enormous impact on global healthcare. Understanding how the proteome changes with biological and chronological age is accelerating progress in this rapidly developing field.

Cardiovascular diseases

Proteomics provides important insights into major health issues like coronary artery disease, atrial fibrillation, and heart failure. These studies advance understanding of the underlying pathways and risk factors and how they link to associated comorbidities.

Immunological and inflammatory diseases

Sensitive, accurate measurement of the plethora of immune response proteins that interact with each other, and multiple cell types is essential to better understand the complexity of immune system responses and the changes underlying autoimmune and inflammatory diseases.

Neurological diseases

Blood and cerebrospinal fluid (CSF) proteomics enable a deeper understanding of disease biology, assessment of risk, diagnosis, and monitoring of key neurological conditions such as Alzheimer’s disease, traumatic brain injury, multiple sclerosis, and chronic pain.

Oncology and immuno-oncology

Adding a much-needed layer of resolution to genomic data, proteomic studies are identifying new diagnostic, prognostic, and long-range risk biomarkers for multiple cancers and providing invaluable insights into the complexities of immuno-oncology.

Next-generation high-throughput proteomics empowers genetically-informed assessment of protein causality and the confident identification of novel drug targets. Adding proteomics to population-scale genetic datasets takes genomics a major step closer to phenotype. This opens new possibilities to explore biological pathways and their interconnections.

Progression from biomarker discovery to development of complex protein signatures for clinical use, involves challenging stages like verification and diverse cohort validation. Traditionally, technology switches hinder progress. Olink’s Proximity Extension Assay (PEA) bridges this gap, offering quality and versatility from discovery to clinical signature development, illustrated by multiple success stories.

Protein biomarker studies accelerate drug discovery and development. They can increase the probability of successfully implementing new therapies by enabling deep knowledge of the biology underlying human disease and providing actionable insights to guide key decision-making.